Abstract
Introduction
Despite the variety of effi cacious oral antidiabetics available to treat type
2 diabetes-many of them available generically-the unmet need in this disease
remains high. In October 2006, the launch of Merck' s Januvia (sitagliptin)
introduced to the U.S. market the newest class of agents to treat this
disease, the dipeptidyl peptidase-IV (DPP-IV) inhibitors, which enjoy several
advantages over their competitors. In this report, we review current and
emerging treatment options for type 2 diabetes and examine the market,
providing data on the uptake of novel branded agents over the last fi ve
years. We focus particularly on Januvia, its current clinical trial data, and
its market uptake since launch; on Novartis' s Galvus and Takeda' s alogliptin,
likely to be Januvia' s most direct competitor; and on the market outlook for
the DPP-IV inhibitor class.
Get the Answers You Need to Shape Your Strategy
The high level of unmet needs in type 2 diabetes offers signifi cant
opportunity for novel agents even at premium prices and despite generic
competition. What are the greatest unmet needs in treatment of type 2
diabetes? Are any emerging therapies likely to fulfi ll these needs? What
benefi ts do current therapies offer diabetic patients, and what are their
drawbacks? Why will metformin continue to be physicians' fi rst choice for fi
rst-line therapy?
The DPP-IV inhibitors offer several advantages over currently available
therapies for type 2 diabetes. In what way are they superior to existing
therapies? What unmet needs can these agents fulfi ll? What drawbacks may
hinder physician uptake of the DPP-IV inhibitors? How are physicians likely to
use these agents? Will they supplant any of the current leading therapies?
Which companies are leading the development of DPP-IV inhibitors? What is the
market outlook for the DPP-IV inhibitors?
Scope
- Current therapies, type 2 diabetes: Metformin (biguanide),
sulfonylureas, peroxisome proliferator-activated receptor-gamma agonists
(Actos, Avandia), glucagon-like peptide-1 analogues (Byetta), advantages,
drawbacks, physician preferences.
- Type 2 diabetes market: 2007 sales and prescriptions, market
leaders, uptake of emerging agents.
- Dipeptidyl peptidase-IV (DPP-IV) inhibitors: Januvia (sitagliptin,
Merck), Galvus (vildagliptin, Novartis), alogliptin (Takeda), and saxagliptin
(BMS, AstraZeneca), mechanism of action, clinical trials data, market uptake,
sales and prescriptions, market outlook. Galvus (vildagliptin,
Novartis)-estimated launch date, clinical trials data. Market outlook for
DPP-IV inhibitors.
Companies Mentioned in This Spectrum Report:
- AstraZeneca
- Bristol-Myers Squibb
- Dainippon Sumitomo
- Eli Lilly
- GlaxoSmithKline
- Merck
- Molteni Farmacetici
- Novartis
- Pfi zer
- Sanofi -Aventis
- Servier
- Takeda
View Cart
